Get the latest news on melanoma


11/6/2018

Rare Genetic Disorder Research Opens Door to Novel Melanoma Therapy

11/6/2018

CheckMate 067 Gives Nivolumab Alone, With Ipilimumab the Nod in Advanced Melanoma

11/5/2018

Quick Take: Phase Ib/II Study of Pembrolizumab and Pegylated Interferon Alfa-2b in Advanced Melanoma

11/3/2018

Melanoma: New guidelines for treatment from the AAD

11/2/2018

Specific CD8 T Cell States May Indicate Response to Melanoma Therapy

11/1/2018

Novartis receives Health Canada approval for the combination therapy of Tafinlar® (dabrafenib) plus Mekinist® (trametinib) for adjuvant treatment of patients with BRAF V600 mutation melanoma(i)

10/22/2018

Follow-up study shows melanoma patients receiving adjuvant dabrafenib plus trametinib experience longer-term relapse-free survival benefit

08/31/2018

Combination Therapy May Offer Alternative Treatment Option for Advanced Melanoma

08/24/2018

Researchers discover epigenetic reason for drug resistance in a deadly melanoma

08/24/2018

Researchers find new therapy to prevent drug resistance for melanoma patients

08/22/2018

Adjuvant Bevacizumab May Not Improve Overall Survival in Resected Melanoma

08/16/2018

Retinoic acid may improve immune response against melanoma

08/15/2018

Alton Memorial to host skin cancer screening Aug. 28

08/13/2018

PD-1 blockade provides ‘dramatic advance’ for the treatment of advanced melanoma

08/08/2018

Is Radioimmunotherapy a Path Forward for Melanoma?

07/27/2018

Keytruda is first I-O drug cleared for melanoma in China

07/26/2018

Cancer cells destroyed with two antipsychotic drugs

07/26/2018

CNDA approves KEYTRUDA for treatment of advanced melanoma

07/18/2018

Melanoma biomarkers predicting checkpoint blocker response

07/13/2018

Melanoma: Immunotherapy for brain metastases ‘doubles survival’

07/12/2018

Immunotherapy doubles survival rates for patients with melanoma brain metastases

07/11/2018

Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab

07/11/2018

Encorafenib, Binimetinib Combination Receives FDA Approval for Mutation-Positive Melanoma

05/19/2018

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

05/10/2018

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

05/01/2018

FDA Approves Adjuvant Combination Treatment For Resected Stage III Melanoma With BRAFV600 Mutations

04/14/2018

Pharmacokinetic drug evaluation of talimogene laherparepvec for the treatment of advanced melanoma.

03/06/2018

Bristol-Myers Squibb’s Opdivo® (nivolumab) Now the First and Only FDA-Approved PD-1 Inhibitor to Offer Every Four-Week Dosing

01/18/2018

Adjuvant Pembrolizumab Improves RFS in Melanoma

01/17/2018

Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial

12/20/2017

FDA Approves Adjuvant Opdivo for Melanoma Treatment

10/06/2017

Amgen’s Imlygic doubles response rate when added to checkpoint therapy

09/11/2017

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

07/24/2017

FDA Approves Ipilimumab for Pediatric Melanoma

07/07/2017

Cancer Breakthrough: Personalized Melanoma Vaccines ‘Safe and Effective’ in First Human Clinical Trials

07/05/2017

Some Respond to Nivolumab After Melanoma Progression

06/29/2017

Study Raises Concern Over Accuracy of Melanoma Diagnoses

06/09/2017

Tanning Bed Use Declining Among U.S. Adults

06/09/2017

Study: Common Surgical Treatment for Melanoma Does Not Improve Patients’ Overall Survival